Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
批准号:
10722599
负责人:
Robert K Ernst
金额:
$23.18万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2025-06-30
关键词:
AcuteAcylationAcyltransferaseAddressAffectAirway DiseaseBacteriaBacterial InfectionsBindingBiological ModelsBiologyCarbonCell DeathCell LineCellsCessation of lifeChronicClinicalCollectionCystic FibrosisDataDevelopmentDimensionsDiseaseDisease OutcomeDisease ProgressionEndotoxemiaEndotoxinsEngineeringEnvironmentEnzymesFamilyFutureGenetic DiseasesGoalsGram-Negative BacteriaHybridsHydroxylationImmuneImmune responseImpairmentIn SituInbred BALB C MiceIndividualInfectionInfection preventionInfiltrationInflammationInflammatoryInflammatory ResponseInnate Immune SystemIronKnowledgeLengthLipid ALipidsLipopolysaccharidesLungLung diseasesLung infectionsLysophospholipidsMacrophageMapsMeasuresMediatingMembraneMetabolicMethodsMucous body substanceMusNeutrophil InfiltrationOutcomeOxidantsPathogenesisPathogenicityPatientsPersonsPhospholipidsPseudomonasPseudomonas aeruginosaPseudomonas aeruginosa infectionPulmonary Cystic FibrosisPulmonary InflammationPulmonary PathologyReceptor CellRegulationReportingRespiratory FailureRoleSeptic ShockSignal TransductionSpecificityStructureStructure of parenchyma of lungTechnologyTestingThickTimeTissuesUnited StatesVariantVirulenceairway inflammationautosomebronchial epitheliumchildren with cystic fibrosischronic infectioncystic fibrosis airwaycystic fibrosis mousecystic fibrosis mucuscystic fibrosis patientscytokinedesignemerging adultexperienceimaging studyin vivoinflammatory markerinnate immune mechanismsmass spectrometermass spectrometric imagingmicrobialmolecular markermortalitymouse modelmultimodalityneutrophilnew therapeutic targetnovelnovel therapeuticspathogenprematurepulmonary functionresponsetargeted treatmenttherapeutic target
中文摘要
项目摘要
持续的急性炎症和慢性感染是囊性纤维化(CF)肺病的标志。
细菌感染导致CF患者气道中的大部分损伤。慢性定植的伪-
铜绿假单胞菌(Pa)与疾病进展和死亡率密切相关,
宿主的先天免疫系统先天免疫细胞驱动这种强烈的炎症,但矛盾的是,
明确病原体,如Pa.我们以前已经证明,从CF儿童中分离出的Pa具有独特的
脂质A结构; CF气道的最早适应之一。脂质A是脂多糖的膜锚,
糖(LPS),并导致内毒素血症、局部组织破坏和败血性休克。此外-
为了早期适应CF气道,观察到高度促炎性、超酰化的脂质A结构,
在大约三分之一的严重气道疾病患者中分离出Pa。的合成
特定的脂质A结构是CF肺病发病机制所必需的,作为炎症产物,
从浸润宿主免疫细胞,如嗜中性粒细胞,需要Pa在厚的厌氧生长。
以及CF肺的含氧粘液不足。本提案的总体目标将加强和扩大我们的
假设在适应CF气道的过程中,Pa合成CF特异性脂质A,
先天免疫机制,导致CF气道的持续性和慢性感染,
中性粒细胞反应的调节可以作为严重气道疾病的控制机制。目标
在该提议中,将首先确定确定致病性和确定的Pa脂质A结构在rele中的信号传导潜力,
vant小鼠模型和CF支气管上皮细胞系,第二,映射和分配结构,以pro-inflam-
使用质谱法测定炎性Pa脂质A在肺病理学发作期间的累积和分布
显像通过定义Pa脂质A结构如何调节宿主的持久性,我们将鉴定新的宿主-
定向治疗(HDT)的目标。
英文摘要
PROJECT SUMMARY
Persistent acute inflammation and chronic infection are hallmarks of Cystic Fibrosis (CF) pulmonary disease.
Bacterial infections cause much of the damage seen in CF patients’ airways. Chronic colonization by Pseudo-
monas aeruginosa (Pa) is strongly associated with disease progression and mortality due to the activation of
the host innate immune system. Innate immune cells drive this strong inflammation but paradoxically fail to
clear pathogens such as Pa. We have previously shown that Pa isolated from children with CF have unique
lipid A structures; one of the earliest adaptations to the CF airway. Lipid A is the membrane anchor of lipopoly-
saccharide (LPS) and is responsible for endotoxemia, localized tissue destruction, and septic shock. In addi-
tion to early adaptation to the CF airway, a highly pro-inflammatory, hyper-acylated lipid A structure is ob-
served in approximately one third of Pa isolated from patients with severe airway disease. The synthesis of
specific lipid A structures is essential to CF lung disease pathogenesis as products of inflammation, derived
from infiltrating host immune cells, such as neutrophils, are required for Pa to grow anaerobically in the thick
and poorly oxygenated mucus of the CF lung. The overall goals of this proposal will strengthen and extend our
hypothesis that during adaptation to the CF airway, Pa synthesizes CF-specific lipid A that alters host
innate immune mechanisms, leading to persistence and chronic infection of the CF airways and that
regulation of the neutrophil response could serve as a control mechanism for severe airway disease. The aims
in this proposal will first, determine pathogenicity and signaling potential of defined Pa lipid A structures in rele-
vant mouse models and CF bronchial epithelial cell lines and, second, map and assign structure to pro-inflam-
matory Pa lipid A as it accumulates and distributes during the onset of lung pathology using mass spectrometry
imaging. By defining how Pa lipid A structures condition the host for persistence, we will identify novel host-
directed therapy (HDT) targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mid-Atlantic Microbial Pathogenesis Meeting 2022
-
批准号:10504721
-
项目类别:
-
资助金额:$1.34万
-
财政年份:2022
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10116273
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10356152
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10570981
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants
-
批准号:9753900
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2016
-
负责人:Robert K Ernst
-
依托单位:
MS diagnostic bacterial identification library
-
批准号:8722128
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2014
-
负责人:Robert K Ernst
-
依托单位:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
-
批准号:8650788
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
-
批准号:8511015
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
-
批准号:8675799
-
项目类别:
-
资助金额:$23.02万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
-
批准号:8584054
-
项目类别:
-
资助金额:$18.04万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Bacterial Lipopolysaccharide Structure
-
批准号:7637607
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2008
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7476478
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7681139
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7911766
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7147812
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7254098
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2000
-
负责人:Robert K Ernst
-
依托单位:
海外基金